

## Submit medical drug prior authorization requests online

As part of our efforts to make the prior authorization (PA) process more efficient, we're encouraging prescribers register and use our Web-based system when prescribing medical drugs for commercial members. This new application gives providers the ability to submit forms electronically and the ability to lookup the status of their medical drug PA request.

### In-state Providers

**In order to be able to submit your prior authorization requests electronically, you will need to:**

- Become a registered Availity user by clicking the following hyperlink, [availity.com/bcbsm](https://www.availity.com/bcbsm), and following the steps.

**To request a drug prior authorization, please go to [bcbsm.com](https://www.bcbsm.com) and follow these easy steps:**

#### Log into the Availity

- Navigate to [availity.com](https://www.availity.com), and enter your provided username and password
- Click the Payer Spaces drop down and select BCBSM BCN icon
- Scroll down the page and select the appropriate Novologix link for your member

#### Complete the Prior Authorization Request

- To login to Novologix, enter your User ID and Password
- Click the Authorizations drop down and select Create Authorization
- Enter in the members specific details and select the correct member on contract
- Complete the required fields and select the correct drug product in the Authorization Lines section
- Click Submit and complete the question to request prior authorization

### Out-of-State Providers

**In order to be able to submit your prior authorization requests electronically, you will need to:**

- Access the Electronic Provider Access (EPA) via local Blues Plan
  - Download the Registration form for electronic access from the Medical Prior Authorization Review link
- AND**
- Submit the Registration form with a completed Medication Authorization Request Form (MARF) via fax or mail
  - For additional information or instructions, please refer to the e-Learning Training Modules in the Provider Secure Services page OR contact the Help Desk at 877-258-3932

Disclaimer: Access is only available to registered users. A valid individual NPI is required for registration.

**Blue Cross Blue Shield/Blue Care Network of Michigan**  
**Medication Authorization Request Form**  
**Radicava® (edaravone) HCPCS CODE: J1301**



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Radicava. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
<b>Name</b>	<b>Name</b>
<b>ID Number</b>	<b>Specialty</b>
<b>D.O.B.</b> <input type="checkbox"/> Male <input type="checkbox"/> Female	<b>Address</b>
<b>Pt weight (in kg)</b> <b>Date recorded:</b> _____	
<b>Diagnosis</b>	<b>City /State/Zip</b>
<b>Drug Name</b>	<b>Phone/Fax: P: (     )     -     F: (     )     -</b>
<b>Dose and Quantity</b>	<b>NPI</b>
<b>Directions</b>	<b>Contact Person</b>
<b>Date of Service(s)</b>	<b>Contact Person Phone / Ext.</b>

**STEP 1: DISEASE STATE INFORMATION**

- Is this request for initiation or continuation of therapy?  Initiation  Continuation *Date patient started therapy:* \_\_\_\_\_
- Site of administration?  Provider office/Home infusion  Other: \_\_\_\_\_  
 Hospital outpatient facility (go to #3) *Reason for Hospital Outpatient administration:* \_\_\_\_\_
- Please specify location of administration if hospital outpatient infusion: \_\_\_\_\_
- Please provide the NPI number for the place of administration: \_\_\_\_\_
- Initiation AND Continuation of therapy:**
  - What is the patient's diagnosis?  
 Amyotrophic Lateral Sclerosis (ALS)  Other, list diagnosis: \_\_\_\_\_
  - When was the diagnosis of ALS established? Date: \_\_\_\_\_
  - Has baseline metrics from the ALSFRS-R (ALS functional rating scale) been submitted?  
 Yes  No
  - Has a lung function test been performed on the patient? (*Please attach any tests results*)  Yes  No
  - What is the patient's percentage predicted forced vital capacity (%FVC) value? \_\_\_\_\_
  - Is the patient currently receiving treatment with Rilutek (riluzole)?  Yes  No
- Continuation request: Radicava start date** \_\_\_\_\_
  - Has a repeat assessment using the ALSFRS-R been done to determine whether the medication is having an effect? (*chart notes are required*)  
 Yes  No *Comment:* \_\_\_\_\_
  - If the patient is continuing therapy, please give the patient's current disease status since beginning treatment:  
 Improved; Please describe: \_\_\_\_\_  
 Stable; Please describe: \_\_\_\_\_  
 Worsened; Please describe: \_\_\_\_\_  
 Other; Please describe: \_\_\_\_\_
- Please add any other supporting medical information necessary for our review*

**Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.**

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

**Physician's Name**

**Physician Signature**

**Date**

<b>Step 2:</b> Checklist	<input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Attached Chart Notes	<input type="checkbox"/> Weight (specify lb or kg), BSA
<b>Step 3:</b> Submit	<b>By Fax: BCBSM Specialty Pharmacy Mailbox</b> <b>1-877-325-5979</b>	<b>By Mail: BCBSM Specialty Pharmacy Program</b> <b>P.O. Box 312320, Detroit, MI 48231-2320</b>

**Confidentiality notice:** This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

3/23/2017; 9/20/2017; 10/11/2018; 11/30/2018; 1/3/2019; 10/1/2020